Skip to content

Krystal Biotech, Inc. KRYS Deferred Tax Assets

Deferred Tax Assets at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$6.73B-20.8%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$5.18B+29.5%
TG Therapeutics logo
TG TherapeuticsTGTX
Incyte logo
IncyteINCY
Gilead Sciences logo
Gilead SciencesGILD
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$10.26B+45.4%
Enterprise value$9.77B+44.2%
P/E45.6×-11.3×
P/S24.6×+3.4×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s deferred tax assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Krystal Biotech, Inc.'s deferred tax assets?
Krystal Biotech, Inc. (KRYS) reported deferred tax assets of $22.82M in Q1 2026.